Sisältöön
tampereen yliopisto: lääketieteen ja biotieteiden tiedekunta: tutkimus: tutkimusryhmät:
Lääketieteen ja biotieteiden tiedekuntaTampereen yliopistoLääketieteen ja biotieteiden tiedekunta

Kirurgia

Professori (urologia):
Teuvo Tammela 
puh. 03-311 64621
teuvo.tammela@uta.fi

Professori (ortopedia ja traumatologia, Seinäjoki):
Harri Pihlajamäki
harri.pihlajamaki@uta.fi

Professori (sydän- ja rintaelinkirurgia):
Jari Laurikka
puh. 03 3116 7669
jari.laurikka@sydansairaala.fi

Apulaisprofessori (verisuonikirurgia):
Niku Oksala
puh. 03-311 64844
niku.oksala@uta.fi

Apulaisprofessori (gastroenterologinen kirurgia):
Johanna Laukkarinen
johanna.laukkarinen@uta.fi

Kliiniset opettajat:
Timo Halonen (plastiikkakirurgia), Seinäjoki, e-mail: timo.halonen@epshp.fi
Ilona Helavirta
(gastroenterologinen kirurgia), ilona.helavirta@uta.fi
Olli Leppänen (käsikirurgia), olli.leppanen@uta.fi
Teemu Murtola
(urologia), e-mail: teemu.murtola@uta.fi
Essi Salonen (ortopedia ja traumatologia), e-mail: essi.salonen@uta.fi


Laboratory of Regenerative Medicine / Kudosregeneraatiolaboratorio >>

Sydän- ja rintaelinkirurgia >>

Urologian tutkimusryhmä >>

Verisuonikirurgia >>

Uusimmat julkaisut:

Saarimäki L, Hugosson J, Tammela TL, Carlsson S, Talala K, Auvinen A
Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
Eur Urol Focus ;2017
PMID

Kilpeläinen TP, Pogodin-Hannolainen D, Kemppainen K, Talala K, Raitanen J, Taari K, Kujala P, Tammela TLJ, Auvinen A
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer.
J Urol ;198(1)50-57, 2017
PMID

Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J
A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
Prostate ;77(11)1213-1220, 2017
PMID

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Oksala N, Pettersson K, Tammela TL
A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Eur J Epidemiol ;2017
PMID

Eskelinen TJ, Kotsar A, Tammela TLJ, Murtola TJ
Components of metabolic syndrome and prognosis of renal cell cancer.
Scand J Urol ;2017
PMID

Tammela TL, Häggman M, Ladjevardi S, Taari K, Isotalo T, Lennernäs H, Weis J, von Below C, Wassberg C, Lennernäs B, Tolf A, Axén N, Gölander CG, Ahlström H
An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
J Urol ;2017
PMID

Lehto US, Aromaa A, Tammela TL
Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment.
Eur J Cancer Care (Engl) ;2017
PMID

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.
Cell Rep ;19(10)2045-2059, 2017
PMID

Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ
The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia.
Prostate ;77(9)1029-1035, 2017
PMID

Kallio J, Hämäläinen M, Luukkaala T, Moilanen E, Tammela TL, Kellokumpu-Lehtinen PL
Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer.
Urol Oncol ;2017
PMID

Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.
Eur Urol Focus ;2017
PMID

Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela TL, Joensuu H, Aspegren J, Mustonen M
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
Eur Urol Focus ;2017
PMID

Nevalainen J, Stenman UH, Tammela TL, Roobol M, Carlsson S, Talala K, Schröder FH, Auvinen A
What explains the differences between centres in the European screening trial? A simulation study.
Cancer Epidemiol ;2017
PMID

Murtola TJ, Vettenranta AM, Talala K, Taari K, Stenman UH, Tammela TLJ, Auvinen A
Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
Eur Urol Focus ;2017
PMID

Murtola TJ, Virkku A, Talala K, Stenman UH, Taari K, Tammela TLJ, Auvinen A
Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
J Urol ;2017
PMID

Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A
Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Scand J Urol ;51(1)5-12, 2017
PMID

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Eur Urol ;71(2)151-154, 2017
PMID

Kinnunen PT, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A
Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Scand J Urol ;50(6)413-419, 2016
PMID

Joentausta RM, Kujala PM, Visakorpi T, Tammela TL, Murtola TJ
Tumor features and survival after radical prostatectomy among antidiabetic drug users.
Prostate Cancer Prostatic Dis ;19(4)367-373, 2016
PMID

Kilpeläinen TP, Talala K, Raitanen J, Taari K, Kujala P, Tammela TL, Auvinen A
Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer.
Am J Epidemiol ;2016
PMID

Syvälä H, Pennanen P, Bläuer M, Tammela TL, Murtola TJ
Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.
Biochem Biophys Res Commun ;481(1-2)46-50, 2016
PMID

Kilpeläinen TP, Mäkinen T, Karhunen PJ, Aro J, Lahtela J, Taari K, Talala K, Tammela TL, Auvinen A
Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer.
Cancer Epidemiol ;2016
PMID

Kaapu KJ, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A
Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Br J Cancer ;115(11)1289-1295, 2016
PMID

Nurminen R, Rantapero T, Wong SC, Fischer D, Lehtonen R, Tammela TL, Nykter M, Visakorpi T, Wahlfors T, Schleutker J
Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.
Genes Chromosomes Cancer ;55(8)661-73, 2016
PMID

Latonen L, Leinonen KA, Grönlund T, Vessella RL, Tammela TL, Saramäki OR, Visakorpi T
Amplification of the 9p13.3 chromosomal region in prostate cancer.
Genes Chromosomes Cancer ;55(8)617-25, 2016
PMID

Pennanen P, Syvälä H, Bläuer M, Savinainen K, Ylikomi T, Tammela TL, Murtola TJ
The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.
Eur J Pharmacol ;2016
PMID

Pöyhönen A, Auvinen A, Häkkinen JT, Koskimäki J, Tammela TL
Population-level and Individual-level Bother of Lower Urinary Tract Symptoms Among 30- to 80-year-old Men.
Urology ;2016
PMID

Pakarainen T, Raitanen J, Talala K, Taari K, Kujala P, Tammela TL, Auvinen A
Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
Eur Urol ;70(3)499-505, 2016
PMID

Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A
5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
Int J Cancer ;138(12)2820-8, 2016
PMID

Sarre S, Määttänen L, Tammela TL, Auvinen A, Murtola TJ
Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.
Scand J Urol ;50(4)267-73, 2016
PMID

Pesonen JS, Cartwright R, Mangera A, Santti H, Griebling TL, Pryalukhin AE, Riikonen J, Tähtinen RM, Agarwal A, Tsui JF, Vaughan CP, Markland AD, Johnson TM, Fonsell-Annala R, Khoo C, Tammela TL, Aoki Y, Auvinen A, Heels-Ansdell D, Guyatt GH, Tikkinen KA
Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis.
Eur Urol ;70(2)372-81, 2016
PMID

Salminen JK, Tammela TL, Auvinen A, Murtola TJ
Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study.
Cancer Causes Control ;27(5)637-45, 2016
PMID

Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, Vuorela A, Nykänen P, Pohjanjousi P, Snapir A, Fizazi K
Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.
Eur Urol ;69(5)834-40, 2016
PMID

Keskiväli T, Kujala P, Visakorpi T, Tammela TL, Murtola TJ
Statin use and risk of disease recurrence and death after radical prostatectomy.
Prostate ;76(5)469-78, 2016
PMID

Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, Gómez Veiga F, Baskin-Bey E, López B, Tombal B
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Eur Urol ;69(4)720-7, 2016
PMID

Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schröder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J
Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
Clin Cancer Res ;22(1)243-9, 2016
PMID

Sjöblom L, Saramäki O, Annala M, Leinonen K, Nättinen J, Tolonen T, Wahlfors T, Nykter M, Bova GS, Schleutker J, Tammela TL, Lilja H, Visakorpi T
Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
PLoS One ;11(3)e0150241, 2016
PMID

Kaapu KJ, Murtola TJ, Määttänen L, Talala K, Taari K, Tammela TL, Auvinen A
Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
Cancer Causes Control ;27(2)157-64, 2016
PMID

Laitinen VH, Akinrinade O, Rantapero T, Tammela TL, Wahlfors T, Schleutker J
Germline copy number variation analysis in Finnish families with hereditary prostate cancer.
Prostate ;76(3)316-24, 2016
PMID

 
Lääketieteen ja biotieteiden tiedekunta, 33014 Tampereen yliopisto
puh. (03) 355 111 (yliopiston vaihde)
Ylläpito: med.info@uta.fi
Muutettu: 21.6.2017 14.52 Muokkaa

Tampereen yliopisto

Tampereen yliopisto
03 355 111
kirjaamo@uta.fi


KARVI-auditoitu HR Excellence in Research

YLIOPISTO
Tutkimus
Opiskelijaksi
Opiskelu
Ajankohtaista
Yhteistyö ja palvelut
Yliopisto

AJANKOHTAISTA
Aikalainen
Avoimet työpaikat
Rehtoriblogi
Tampere3

PALVELUT
Aktuaarinkanslia
Avoin yliopisto
Hallinto
Kansainvälisen koulutuksen keskus
Kielikeskus
Kielipalvelut
Kirjaamo
Kirjasto
Liikuntapalvelut
Viestintä
Tietohallinto
Tutkimuspalvelut
Täydennyskoulutus
Tietoarkisto
» lisää palveluita

OPISKELU
Opetusohjelma
Opinto-oppaat
Opiskelijan työpöytä

SÄHKÖISET PALVELUT
Andor-hakupalvelu
Andor - uusi lainasi
Intra
Moodle (learning2)
NettiOpsu / NettiRekka
NettiKatti
Sähköinen tenttipalvelu
TamPub
Office 365 webmail
Utaposti webmail
Wentti